Opes Wealth Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Opes Wealth Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$318K	Sell	10,945 -3,500	-24%	-$102K	0.05%	114
2025 Q4	$378K	Hold	14,445	–	–	0.06%	108
2025 Q3	$341K	Hold	14,445	–	–	0.06%	110
2025 Q2	$296K	Hold	14,445	–	–	0.05%	122
2025 Q1	$296K	Buy	14,445 +4,200	+41%	+$93.7K	0.06%	119
2024 Q4	$232K	Hold	10,245	–	–	0.05%	125
2024 Q3	$252K	Hold	10,245	–	–	0.05%	118
2024 Q2	$237K	Hold	10,245	–	–	0.05%	120
2024 Q1	$247K	Buy	10,245 +1,400	+16%	+$32.8K	0.06%	117
2023 Q4	$204K	Buy	+8,845	New	+$178K	0.05%	124
2022 Q4	–	Sell	-7,595	Closed	-$200K	–	106
2022 Q3	$200K	Buy	+7,595	New	+$234K	0.08%	90
2022 Q2	–	Sell	-6,595	Closed	-$227K	–	97
2022 Q1	$227K	Buy	6,595 +1,175	+22%	+$41.5K	0.07%	95
2021 Q4	$237K	Buy	+5,420	New	+$257K	0.07%	99

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Opes Wealth Management's IDNA Position: Q1 2026 in Review

Opes Wealth Management reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 24% in Q1 2026, selling an estimated $102K and leaving 10,945 shares worth $318K. The position accounts for 0.05% of the portfolio, ranked #114.

Opes Wealth Management first reported a position in IDNA in Q4 2021 and has held it in 13 quarters since. The position peaked at $378K in Q4 2025. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Opes Wealth Management held 10,945 shares of iShares Genomics Immunology and Healthcare ETF worth $318K as of Q1 2026.
Opes Wealth Management sold 3,500 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $102K.
iShares Genomics Immunology and Healthcare ETF made up 0.05% of Opes Wealth Management's portfolio in Q1 2026, its #114 holding.
Opes Wealth Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and has held it in 13 quarters since.
Opes Wealth Management's iShares Genomics Immunology and Healthcare ETF position peaked at $378K in Q4 2025.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Opes Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.